Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.

Inhaled Corticosteroids in Children with Asthma: Pharmacologic Determinants of Safety and Efficacy and Other Clinical Considerations

Gulliver, Tanya, Morton, Ronald, Eid, Nemr · 2007 · Pediatric Drugs

Abstract

The role of inhaled corticosteroids (ICS) in the treatment of childhood asthma has been well established. An ideal corticosteroid should demonstrate high pulmonary deposition and residency time, in addition to a low systemic bioavailability and rapid systemic clearance. The lung depositions of the ICS have been compared, with beclomethasone (beclometasone)-hydrofluoroalkane (HFA) and ciclesonide showing the highest lung deposition. Lung deposition is influenced by not only the inhalation device and type of propellant (HFA or chlorofluorocarbon), but also by whether the aerosol is a solution or suspension, and the particle size of the respirable fraction. Pulmonary residency time increases when budesonide and des-ciclesonide undergo reversible fatty acid esterification. The bioavailability of the drug depends on the oral bioavailable fraction and the amount absorbed directly from the pulmonary vasculature. The clearance rate of des-ciclesonide is very high (228 L/h), increasing its safety profile by utilizing extra-hepatic clearance mechanisms. Both des-ciclesonide and mometasone have a high protein binding fraction (98-99%). The volume of distribution (Vd) is proportional to the lipophilicity of the drug, with the Vd of fluticasone being 332L compared with 183L for budesonide. Increasing the Vd will also increase the elimination half-life of a drug. The pharmacodynamics of ICS depend on both the receptor binding affinity and the dose-response curve. Among the ICS, fluticasone and mometasone have the highest receptor binding affinity (1800 and 2200, respectively), followed by budesonide at 935 (relative to dexamethasone = 100). Compared with other nonsteroid asthma medications (long-acting beta-agonists, theophylline, and montelukast) ICS have proven superiority in improving lung function, symptom-free days, and inflammatory markers. One study suggests that early intervention with ICS reduces the loss in lung function (forced expiratory volume in 1 second) over 3 years. Whether airway remodeling is reduced or prevented in the long term is unknown. Potential adverse drug effects of ICS include adrenal and growth suppression. While in low-to-medium doses ICS have shown little suppression of the adrenal pituitary axis, in high doses the potential for significant adrenal suppression and adrenal crisis exists. Several longitudinal studies evaluating the effect of ICS on growth have shown a small decrement in growth velocity (approximate 1-2 cm) during the first year of treatment. However, when investigators followed children treated with budesonide for up to 10 years, no change in target adult height was noted. In conclusion, the development of optimal delivery devices for young children, as well as optimizing favorable pharmacokinetic properties of ICS should be priorities for future childhood asthma management.

Overview

Integrity signals

Registry

Crossref · 10.2165/00148581-200709030-00007

Cites

100 of 100 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 100 references

Research works printed but not linked: 6

  1. Ryrfeldt, 1982, Eur J Respir Dis Suppl, 122, 86
  2. Kelly, 1999, Respir Care Clin N Am, 5, 537
  3. Griffioen, 1998, Ned Tijdschr Geneeskd, 142, 1484
  4. Miller-Larsson, 2003, Am J Respir Crit Care Med, 167, A773
  5. Tunek, 1997, Drug Metab Dispos, 25, 1311
  6. Derendorf, 2005, Allergy Asthma Proc, 26, 89

Cited by

See all 47

Metadata

Authors
Gulliver, T., Morton, R., & Eid, N.
Affiliations
  • John Hunter Children's Hospital (AU)
  • University of Louisville (US)
Corresponding author
Eid, Nemr
Venue
Pediatric Drugs
Published
2007
Volume
9
Issue
3
Pages
185-194
ISSN
1174-5878 (ISSN-L)
OpenAlex
W613309803
Cited by
47
References
100
Citations by year
2026: 1 · 2025: 2 · 2024: 1 · 2021: 2 · 2018: 2 · 2017: 3 · 2016: 3 · 2015: 1 · 2013: 2 · 2012: 6
FWCI
1.05
Type
journal article
Language
en
Open access
closed
Locations
  • Pediatric Drugs (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Standards and Technology
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Keywords
inhaled corticosteroids, childhood asthma, lung deposition, beclomethasone, ciclesonide, mometasone, fluticasone, budesonide, pharmacokinetics, pharmacodynamics, adrenal suppression, growth inhibition, airway remodeling, long-acting beta2-agonists, corticosteroid adverse effects
MeSH terms
Administration, Inhalation, Adrenal Cortex Hormones, Asthma, Child, Humans

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhaled Corticosteroids in Children with Asthma: Pharmacologic Determinants of Safety and Efficacy and Other Clinical Considerations. https://app.cochat.ai/papers/10.2165/00148581-200709030-00007
The paper
Gulliver, T., Morton, R., & Eid, N. (2007). Inhaled Corticosteroids in Children with Asthma: Pharmacologic Determinants of Safety and Efficacy and Other Clinical Considerations. Pediatric Drugs. https://doi.org/10.2165/00148581-200709030-00007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.